Published in Ann Intensive Care on July 04, 2012
Mortality of patients infected with HIV in the intensive care unit (2005 through 2010): significant role of chronic hepatitis C and severe sepsis. Crit Care (2014) 0.91
Etiology and Outcome of Patients with HIV Infection and Respiratory Failure Admitted to the Intensive Care Unit. Interdiscip Perspect Infect Dis (2013) 0.81
Critical care of persons infected with the human immunodeficiency virus. Clin Chest Med (2013) 0.79
Clinical review: Respiratory failure in HIV-infected patients--a changing picture. Crit Care (2013) 0.78
Palliative care for patients with HIV/AIDS admitted to intensive care units. Rev Bras Ter Intensiva (2016) 0.75
Clinical Characteristics and Short-Term Outcomes of HIV Patients Admitted to an African Intensive Care Unit. Crit Care Res Pract (2016) 0.75
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
Intensive care of patients with HIV infection. N Engl J Med (2006) 2.86
Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy. Chest (2004) 2.26
Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS (2003) 2.18
Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med (2002) 2.12
Survival for patients With HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest (2008) 1.94
Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS (2004) 1.73
Current issues in critical care of the human immunodeficiency virus-infected patient. Crit Care Med (2006) 1.62
Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis (1986) 1.61
Early predictors of outcome for HIV patients with neurological failure. JAMA (1995) 1.40
Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med (2000) 1.39
Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax (2006) 1.35
Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy. Thorax (2007) 1.30
Outcome of critically ill human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. J Intensive Care Med (2005) 1.29
Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era. Intensive Care Med (2004) 1.27
Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Crit Care Med (2009) 1.24
Pneumocystis carinii pneumonia and respiratory failure in AIDS. Improved outcomes and increased use of intensive care units. Am Rev Respir Dis (1991) 1.23
Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era. Crit Care (2010) 1.20
Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients. Eur J Clin Microbiol Infect Dis (2002) 1.05
Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr (2005) 1.04
Septic shock in patients with the acquired immunodeficiency syndrome. Intensive Care Med (1997) 0.98
Improving outcome of human immunodeficiency virus-infected patients in a Mexican intensive care unit. Arch Med Res (2007) 0.97
Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients. Eur Respir J (2001) 0.96
Short- and long-term outcome of HIV-infected patients admitted to the intensive care unit. Eur J Clin Microbiol Infect Dis (2011) 0.89
Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science (2007) 5.07
Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA (2002) 4.48
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
An intervention to decrease complications related to endotracheal intubation in the intensive care unit: a prospective, multiple-center study. Intensive Care Med (2009) 3.24
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med (2009) 3.07
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol (2006) 2.82
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis (2003) 2.54
Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J (2007) 2.37
Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr (2004) 2.12
Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol (2012) 2.02
Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis (2012) 1.97
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS One (2010) 1.86
Adverse outcomes of interrupted precordial compression during automated defibrillation. Circulation (2002) 1.63
Optimal use of maraviroc in clinical practice. AIDS (2008) 1.60
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood (2011) 1.49
Reasons for early abacavir discontinuation in HIV-infected patients. Ann Pharmacother (2003) 1.47
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS (2009) 1.46
Suppression of HIV-1 replication by microRNA effectors. Retrovirology (2009) 1.44
Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial. Am J Respir Crit Care Med (2015) 1.44
Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity and mortality. Eur Heart J (2006) 1.43
Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci U S A (2002) 1.42
Monoclonal Gammopathy in HIV-1-Infected Patients: Factors Associated With Disappearance Under Long-Term Antiretroviral Therapy. J Acquir Immune Defic Syndr (2015) 1.40
Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother (2009) 1.39
Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS (2007) 1.27
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS (2013) 1.26
Zika virus infections in three travellers returning from South America and the Caribbean respectively, to Montpellier, France, December 2015 to January 2016. Euro Surveill (2016) 1.19
Predicting the success of defibrillation by electrocardiographic analysis. Resuscitation (2002) 1.18
Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis (2007) 1.17
Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals. Blood (2013) 1.14
The impact of valve surgery on short- and long-term mortality in left-sided infective endocarditis: do differences in methodological approaches explain previous conflicting results? Eur Heart J (2009) 1.14
Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr (2004) 1.13
Introduction of SARS in France, March-April, 2003. Emerg Infect Dis (2004) 1.10
Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur J Paediatr Neurol (2011) 1.08
Severe metabolic or mixed acidemia on intensive care unit admission: incidence, prognosis and administration of buffer therapy. A prospective, multiple-center study. Crit Care (2011) 1.08
Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. J Acquir Immune Defic Syndr (2008) 1.06
Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients. Retrovirology (2007) 1.06
Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. J Hepatol (2012) 1.05
Mycobacterium heckeshornense tenosynovitis. Scand J Infect Dis (2006) 1.05
Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr (2005) 1.04
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis (2011) 1.04
Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol (2005) 1.03
Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clin Infect Dis (2012) 1.02
Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo. AIDS (2003) 1.01
Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. J Acquir Immune Defic Syndr (2012) 0.98
Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. AIDS (2012) 0.98
Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study. J Thorac Oncol (2011) 0.97
CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS (2009) 0.96
Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). Int J Epidemiol (2014) 0.96
Detection and identification of Candida spp. in human serum by LightCycler real-time polymerase chain reaction. Diagn Microbiol Infect Dis (2007) 0.94
Molecular evidence that nasal carriage of Staphylococcus aureus plays a role in respiratory tract infections of critically ill patients. J Clin Microbiol (2005) 0.94
DNAGear--a free software for spa type identification in Staphylococcus aureus. BMC Res Notes (2012) 0.94
Multicytokine detection improves latent tuberculosis diagnosis in health care workers. J Clin Microbiol (2012) 0.93
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS (2004) 0.93
A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant (2009) 0.92
Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. AIDS (2002) 0.92
Nocardia veterana isolated from ascitic fluid of a patient with human immunodeficiency virus infection. J Clin Microbiol (2003) 0.92
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J Infect Dis (2003) 0.91
Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS (2004) 0.91
The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5. AIDS (2008) 0.90
Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. J Thorac Oncol (2010) 0.90
Whipple's endocarditis as a complication of tumour necrosis factor-alpha antagonist treatment in a man with ankylosing spondylitis. Rheumatology (Oxford) (2010) 0.89
Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count. Cytometry B Clin Cytom (2009) 0.89
Acute respiratory failure in kidney transplant recipients: a multicenter study. Crit Care (2011) 0.89
Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology (2012) 0.89
6 cmH2O continuous positive airway pressure versus conventional oxygen therapy in severe viral bronchiolitis: a randomized trial. Pediatr Pulmonol (2012) 0.88
Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patients. J Acquir Immune Defic Syndr (2004) 0.87
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother (2011) 0.87
Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis (2004) 0.87
Pulmonary cryptococcosis in a patient with Crohn's disease treated with prednisone, azathioprine and adalimumab: exposure to chicken manure as a source of contamination. J Crohns Colitis (2012) 0.86
Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy. AIDS (2003) 0.86
Isolation of a protozoan parasite genetically related to the insect trypanosomatid Herpetomonas samuelpessoai from a human immunodeficiency virus-positive patient. J Clin Microbiol (2008) 0.85
Rise of CC398 lineage of Staphylococcus aureus among Infective endocarditis isolates revealed by two consecutive population-based studies in France. PLoS One (2012) 0.85
Enumeration of latently infected CD4+ T cells from HIV-1-infected patients using an HIV-1 antigen ELISPOT assay. J Clin Virol (2004) 0.85
High CD4(+) T-cell surface CXCR4 density as a risk factor for R5 to X4 switch in the course of HIV-1 infection. J Acquir Immune Defic Syndr (2010) 0.85
Quality assessment in intensive care units: proposal for a scoring system in terms of structure and process. Intensive Care Med (2007) 0.85
Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther (2002) 0.85
The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr Opin HIV AIDS (2009) 0.85
Investigation of minor species Candida africana, Candida stellatoidea and Candida dubliniensis in the Candida albicans complex among Yaoundé (Cameroon) HIV-infected patients. Mycoses (2014) 0.84
Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individuals. J Virol (2004) 0.84
Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infection. AIDS (2003) 0.84
Superoxide anion overproduction in sepsis: effects of vitamin e and simvastatin. Shock (2004) 0.84
Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antivir Ther (2013) 0.84
Rhodococcus equi brain abscess in an immunocompetent patient. Scand J Infect Dis (2002) 0.84